Home > MCRI > Clinical Research Using a Neonicitenoid (Capstar, Nitenpyram)

Dr. Lance Adams , Aquarium of the Pacific | Lisa Bartley, Cabrillo Marine Aquarium

Clinical Research Using a Neonicitenoid (Capstar, Nitenpyram)

to Treat Parasitic Infections of Lernea sp. Copepods (2004)

The neonicitenoids target invertebrate specific GABA activated chloride channels in the central nervous system and cause paralysis. Neonicitinoids like Advantage are currently the gold standard for treatment of fleas (arthropods) in dogs and cats. Preliminary data shows that an oral dose of 10-30 mg/kg weekly is safe for the fish used in the study and is effective in eliminating 100 percent of Lernea sp. copepods within seven to ten days of treatment.

Last updated October 19 2011